{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

Assessment of Lifestyle and PHArmacological Approaches in HyperUricemiA with Chronic Kidney Disease (ALPHA-UA)

Survey Questionnaire Form
Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

Questionnaire

  1. What is the prevalence of hyperuricemia overall (without CKD) based on your clinical experience and available data? *

  2. Which demographic age group do you find most affected by hyperuricemia overall (without CKD) in your practice? (Tick multiple-options, if applicable)*

  3. Describe your clinical approach to diagnosing hyperuricemia in patients without obvious symptoms. *
  4. What % of your stage 1 & 2 CKD patients have undiagnosed Hyperuricemia? *

  5. How do you integrate the management of hyperuricemia into your overall patient care plan? *
  6. What are the common risk factors for developing hyperuricemia in your patients? (Tick multiple-options, if applicable) *

  7. How do you diagnose hyperuricemia in your clinical practice? (Tick multiple-options, if applicable) *

  8. Which comorbid conditions are most commonly associated with hyperuricemia in your patients? (Tick multiple-options, if applicable) *

  9. Which dietary factors do you find most likely to contribute to hyperuricemia in your patients? (Tick multiple-options, if applicable) *

  10. What strategies do you use to educate patients about hyperuricemia and its potential complications? *
  11. What lifestyle modifications do you typically recommend for patients with hyperuricemia? (Tick multiple-options, if applicable) *

  12. What is your first-line pharmacological treatment for hyperuricemia? *

  13. What is the impact of obesity on hyperuricemia in your patients? *

  14. What are the long-term complications of untreated hyperuricemia that you observe in your patients? (Tick multiple-options, if applicable) *

  15. How do you handle cases where hyperuricemia coexists with other metabolic disorders? *
  16. How do you approach the treatment of asymptomatic hyperuricemia in your practice? (Tick multiple-options, if applicable) *

  17. Do you observe any differences in prevalence of hyperuricemia based on gender? *

  18. What is the relationship between hyperuricemia and cardiovascular disease based on your clinical observations? *

  19. How do you prioritize treatment for hyperuricemia in patients with multiple comorbidities? *
  20. How do you differentiate between asymtomaic gout and hyperuricemia in your clinical practice? *
  21. How frequently do you monitor serum uric acid levels in CKD patients undergoing treatment for hyperuricemia? *

  22. In what ways do you involve patients in their own management of hyperuricemia? *
  23. How effective do you believe early intervention with RAAS inhibitors is in preventing CKD progression in diabetic patients? *

  24. How do diuretics affect uric acid levels? *

  25. What role do you believe genetics play in the development of hyperuricemia based on your clinical experience? *
  26. How strongly do you agree that hyperuricemia accelerates renal progression and microvascular injury, leading to endothelial dysfunction and renal arteriolopathy? *

  27. How strongly do you agree that increased serum uric acid levels are an independent risk factor for CKD and cardiovascular disease, and that treating hyperuricemia might help prevent CKD progression and endothelial injury? *

  28. How strongly do you agree that xanthine oxidase inhibitors delay the decline of renal function and reduce the risk of cardiovascular events among patients with CKD? *

  29. How do you determine the initial dose of Febuxostat for a newly diagnosed hyperuricemia patient? *

  30. What is the frequency of patient monitoring for Febuxostat dose adjustment? *

  31. How do you address patient adherence to hyperuricemia treatment plans? *
  32. In your clinical practice, what is the most common stage of CKD in patients on Febuxostat? (Tick multiple-options, if applicable)*

  33. At what uric acid level do you prescribe Febuxostat 80 mg? *

  34. At what uric acid level do you prescribe Febuxostat 40 mg? *

  35. For how long do you typically prescribe Febuxostat in hyperuricemia patients with CKD? *

  36. After controlling hyperuricemia, what is your strategy to maintain uric acid levels in your patients? *

  37. What are the most common misconceptions about hyperuricemia that you encounter among your patients? *
  38. What common side effects of Febuxostat should patients be made aware of in your experience? *

  39. In which patient population do you prefer prescribing Febuxostat over Allopurinol? *

  40. What role do you see for Febuxostat in patients with hyperuricemia in gout? (Tick multiple-options, if applicable)*

  41. How has your approach to hyperuricemia management evolved over the years? *
  42. What target serum uric acid level do you aim for in patients on Febuxostat therapy? *

  43. How long do you typically continue Febuxostat therapy after achieving target serum uric acid levels? *

  44. How do you handle cases of elevated liver enzymes in patients undergoing Febuxostat therapy? *

  45. Which drug do you prefer for managing hyperuricemia in patients with a history of severe cardiovascular disease? Give the reason for your choice *
  46. What challenges do you face in the treatment of hyperuricemia among patients with limited access to healthcare resources? *
  47. What additional therapies do you consider for patients on Febuxostat who do not reach target uric acid levels? (Tick multiple-options, if applicable)*

  48. In your clinical experience with uric acid urolithiasis, which treatment approach do you find most effective?*

  49. Can you share a case where managing hyperuricemia significantly improved a patient’s quality of life? *
  50. What future advancements in the treatment of hyperuricemia are you most looking forward to? *
{{-- --}}